{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:46Z","timestamp":1794893626901,"version":"4.9.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite high response rates, anti\u2013programmed death 1 (anti\u2013PD-1) monotherapy eventually fails in most patients with relapsed\/refractory (R\/R) Hodgkin lymphoma (HL) and is ineffective in most other B-cell malignancies. The lymphocyte activation gene 3 (LAG-3) cell-surface receptor represents another immune checkpoint that can be targeted to induce remissions in these diseases; dual inhibition of PD-1 and LAG-3 is approved in advanced melanoma. We performed a multicenter phase 1\/2a open-label study of the anti\u2013LAG-3 antibody relatlimab (RELATIVITY-022) administered as monotherapy or in combination with nivolumab in patients with R\/R B-cell malignancies. We treated 106 patients and no dose-limiting toxicities were observed during escalation. The recommended phase 2 dose was relatlimab 240 mg as monotherapy or nivolumab 240 mg plus relatlimab 160 mg, administered every 2 weeks. No unexpected safety signals were observed compared with anti\u2013PD-1 monotherapy. In the HL expansion cohorts, objective response rate (ORR) was 62% and complete response rate (CRR) was 19% in anti\u2013PD-1\/anti\u2013programmed death ligand 1 (anti\u2013PD-[L]1)\u2013naive patients (n = 21), with a median progression-free survival (PFS) of 19 months; ORR was 15% and CRR 0%, with median PFS of 6 months in anti\u2013PD-(L)1-progressed patients (n = 20). In diffuse large B-cell lymphoma, ORR was 7% with no CRs (n = 15), and median PFS was 2 months. Nivolumab plus relatlimab appeared to be safe and tolerable. Responses in patients with anti\u2013PD-(L)1\u2013naive HL was encouraging, although the contribution of relatlimab to overall efficacy of the combination needs to be further evaluated. This trial was registered at www.ClinicalTrials.gov as #NCT02061761.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015086","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:07:21Z","timestamp":1741014441000},"page":"3383-3394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology, Department of Medicine\/Clinical Research Division, University of Washington\/Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"2Division of Lymphoma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"3Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Spurgeon","sequence":"additional","affiliation":[{"name":"5Division of Hematology & Medical Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health and Science Center, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"6Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"7Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"8Hematology and Oncology Division, Medicine Department, Weill Cornell, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold B.","family":"Gelb","sequence":"additional","affiliation":[{"name":"9Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Ahmed","sequence":"additional","affiliation":[{"name":"10Oncology Clinical Science, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Dong","sequence":"additional","affiliation":[{"name":"11Biostatistics, Oncology, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Praneeth","family":"Bathena","sequence":"additional","affiliation":[{"name":"12Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasika","family":"Suryawanshi","sequence":"additional","affiliation":[{"name":"13Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny Qun","family":"Wu","sequence":"additional","affiliation":[{"name":"14Solid Tumor Translation Medicine\/Oncology Biomarker Development, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheen","family":"Wang","sequence":"additional","affiliation":[{"name":"15Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[{"name":"16Division of Hematologic Malignancies, Northwell Health, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"10","key":"2025070811220124400_bib1","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025070811220124400_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2025070811220124400_bib3","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025070811220124400_bib4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025070811220124400_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"2025070811220124400_bib6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025070811220124400_bib7","author":"OPDIVO (nivolumab)","year":"2023"},{"key":"2025070811220124400_bib8","author":"KEYTRUDA (pembrolizumab)","year":"2023"},{"issue":"34","key":"2025070811220124400_bib9","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025070811220124400_bib10","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"issue":"suppl 3","key":"2025070811220124400_bib11","first-page":"50","article-title":"P125 (0116) Nivolumab re-treatment in patients with relapsed\/refractory Hodgkin lymphoma [abstract]","volume":"2","author":"Ansell","year":"2018","journal-title":"Hemasphere"},{"issue":"11","key":"2025070811220124400_bib12","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3324\/haematol.2019.242529","article-title":"Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation","volume":"105","author":"Manson","year":"2020","journal-title":"Haematologica"},{"issue":"14","key":"2025070811220124400_bib13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2025070811220124400_bib14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"issue":"4","key":"2025070811220124400_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"2025070811220124400_bib16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T-cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J Immunol"},{"issue":"12","key":"2025070811220124400_bib17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased programmed death-1+ tumor-infiltrating lymphocytes in classic Hodgkin lymphoma substantiate reduced overall survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum Pathol"},{"issue":"8","key":"2025070811220124400_bib18","doi-asserted-by":"crossref","first-page":"e1026530","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin's lymphomas","volume":"4","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"issue":"10","key":"2025070811220124400_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025070811220124400_bib20","first-page":"86","article-title":"Lymphoma epidemiology: recent advances and future directions","volume":"52","author":"Scott","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"23","key":"2025070811220124400_bib21","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025070811220124400_bib22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"key":"2025070811220124400_bib23","author":"OPDUALAG (nivolumab and relatlimab-rmbw)","year":"2022"},{"key":"2025070811220124400_bib24","unstructured":"World Health Organization\n          . Timeline of WHO's response to COVID-19. 2020. Accessed 11 September 2023. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/interactive-timeline."},{"key":"2025070811220124400_bib25","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009. Accessed 22 September 2021. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"issue":"5","key":"2025070811220124400_bib26","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025070811220124400_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"issue":"23","key":"2025070811220124400_bib28","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025070811220124400_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","article-title":"The latest option: nivolumab and relatlimab in advanced melanoma","volume":"25","author":"Albrecht","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"27","key":"2025070811220124400_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2025070811220124400_bib31","doi-asserted-by":"crossref","first-page":"e19015","DOI":"10.1200\/JCO.2019.37.15_suppl.e19015","article-title":"Retrospective comparison of Cheson 2007 and Lugano classification criteria in independent review assessment of FDG-avid lymphomas [abstract]","volume":"37","author":"Narang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2025070811220124400_bib32","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2022.40.16_suppl.7516","article-title":"Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with anti\u2013PD-1\u2013naive relapsed or refractory (R\/R) classic Hodgkin lymphoma (CHL): an open-label phase 1\/2 study [abstract]","volume":"40","author":"Johnson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2025070811220124400_bib33","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1200\/JCO.2022.40.16_suppl.7545","article-title":"Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with relapsed or refractory (R\/R) classic Hodgkin lymphoma (CHL) after anti\u2013PD-1 treatment: an open-label phase 1\/2 study [abstract]","volume":"40","author":"Timmerman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025070811220124400_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025070811220124400_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/10428194.2022.2136956","article-title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","volume":"64","author":"Kuruvilla","year":"2023","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3383\/2401706\/blooda_adv-2024-015086-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3383\/2401706\/blooda_adv-2024-015086-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:22:14Z","timestamp":1751973734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3383\/535818\/Nivolumab-plus-relatlimab-for-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015086","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,7,8]]}}}